Human antibodies against eotaxin and their use

Abstract

Specific binding members directed to eotaxin-1, in particular human antibodies and antibody fragments against human eotaxin-1 and especially those which neutralise eotaxin-1 activity. The antibodies VH and/or VL domain of the scFv fragment herein termed CAT-212 and of the IgG4 antibody herein termed CAT 213. One or more complementary determining regions (CDRs) of the CAT-212/-213 VH and/or VL domains, especially VH CRD3 in other antibody framework regions. Compositions containing specific binding members, and their use in methods of inhibiting or neutralising eotaxin, including methods of treatment of the human or animal body by therapy.

1 . A specific binding member that binds human eotaxin and which comprises an antibody VH domain selected from the group consisting of the CAT-212 VH domain (SEQ ID NO. 2), and a VH domain comprising one or more VH CDR*'s with an amino acid sequence selected from SEQ ID NO. 5, SEQ ID NO. 6 and SEQ ID NO. 7; and/or an antibody VL domain selected from the group consisting of the CAT-212 VL domain (SEQ ID NO. 4), and a VL domain comprising one or more VL CDR's with an amino acid sequence selected from SEQ ID NO. 8, SEQ ID NO. 9 and SEQ ID NO. 10. 
     
     
         2 .- 11 . (canceled) 
     
     
         12 . An isolated nucleic acid which comprises a nucleotide sequence encoding a specific binding member or antibody VH or VL domain of a specific binding member according to  claim 1 . 
     
     
         13 . A host cell transformed with nucleic acid according to  claim 12 . 
     
     
         14 .- 29 . (canceled)